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The Dio3 gene, which encodes for the type 3 deiodinase (D3), controls thyroid hormone (TH)
availability. The lack ofD3 inmice results in tissue overexposure to THand abroadneuroendocrine
phenotype. Dio3 is an imprinted gene, preferentially expressed from the paternally inherited
allele in the mouse fetus. However, heterozygous mice with paternal inheritance of the inacti-
vating Dio3 mutation exhibit an attenuated phenotype when compared with that of Dio3 null
mice. To investigate this milder phenotype, the allelic expression of Dio3was evaluated in differ-
ent mouse tissues. Preferential allelic expression of Dio3 from the paternal allele was observed in
fetal tissues and neonatal brain regions, whereas the biallelic Dio3 expression occurred in the
developing eye, testes, and cerebellum and in the postnatal brain neocortex, which expresses a
larger Dio3 mRNA transcript. The newborn hypothalamus manifests the highest degree of Dio3
expression from the paternal allele, compared with other brain regions, and preferential allelic
expression of Dio3 in the brain relaxed in late neonatal life. A methylation analysis of two
regulatory regions of the Dio3 imprinted domain revealed modest but significant differences
between tissues, but these did not consistently correlate with the observed patterns ofDio3 allelic
expression. Deletion of the Dio3 gene and promoter did not result in significant changes in the
tissue-specific patterns of Dio3 allelic expression. These results suggest the existence of unidenti-
fied epigenetic determinants of tissue-specificDio3 imprinting. The resulting variation in theDio3
allelic expression between tissues likely explains the phenotypic variation that results from pater-
nal Dio3 haploinsufficiency. (Molecular Endocrinology 28: 1875–1886, 2014)
The type 3 deiodinase (D3)modulates thyroid hormone(TH) action by converting both the prohormone T4
and the active hormone T3 into inactive metabolites (1–
3). Its high expression in the pregnant uterus, fetus, and
placenta (4, 5) and in the developing and adult central
nervous system (CNS) (6, 7) suggests that D3 is important
for the maintenance of appropriate levels of TH in the
fetus and the adult. In this regard, we have shown that
mice lacking D3 (D3KO or Dio3/ mice) are overex-
posed to T3 during development and subsequently mani-
fest marked deficits in the maturation and function of the
thyroid axis, severe growth retardation, and impaired vi-
ability and fertility (8, 9). These mice also exhibit altera-
tions in cardiovascular (10) and sensory functions (11,
12), glucose and insulin homeostasis (13), and brain gene
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expression patterns (14, 15), demonstrating a critical role
for D3 in many pathophysiological outcomes.
We and others have demonstrated that Dio3, the gene
that codes for D3, is subject to genomic imprinting in the
mouse (16, 17). Genomic imprinting is an epigenetic phe-
nomenon that affects a small percentage of mammalian
genes (18–20). Imprinted genes are preferentially or ex-
clusively expressed from one of the alleles, depending on
the parental origin (18). Although themechanisms under-
lying genomic imprinting are not fully understood, a com-
mon feature of imprinted loci is the differential methyl-
ation (imprint) between parental alleles in key regulatory
genomic sequences. These imprints ultimately translate
into the allele-specific expression or repression of certain
genes within the imprinted domain (18–20). Genomic
imprinting results in a high degree of monoallelic gene
expression, and thus poses a higher risk of pathologies, as
a random mutation in just one copy of the imprinted
gene may lead to deleterious loss or gain of function.
Furthermore, alterations in the dosage of imprinted
genes due to disrupted genomic imprinting result in
abnormalities in development and adult physiology
(21, 22). In humans, aberrant genomic imprinting is the
cause of severe developmental, neurological, and met-
abolic syndromes (23–27).
Dio3 belongs to the Dlk1-Dio3 imprinted domain
(28), and in the mouse fetus, it is expressed preferentially
from the allele inherited from the father (16, 17). How-
ever, the repression of the maternal Dio3 allele is not
complete (17), and in the placenta, considerable expres-
sion originates from the maternal allele (29), indicating
thatDio3 imprinting in this tissue is significantly relaxed.
We have also reported a lesser degree of genomic imprint-
ing in the heads of fetal mice (17). Taken together, these
observations suggest that allelic contributions to Dio3
expression vary in a tissue-specific pattern, with resultant
functional and phenotypic implications. In the context of
the milder gross phenotype that we observe in heterozy-
gous mice with a mutated paternalDio3 allele when com-
pared with that of null Dio3 mice, herein we use our
previously described D3KO mouse and a second novel
model of targetedDio3 disruption to analyzeDio3 allelic
expression in various tissues and in regions of the CNS.
We show that Dio3 imprinting varies significantly be-
tween tissues and developmental stages, especially in the
CNS. This suggests that epigenetic information regulates
Dio3 expression in a tissue- and/or cell-specific manner
and that the resultant alterations in the imprinting pattern
of Dio3 effect developmental outcomes.
Materials and Methods
Animals, genotyping, and tissue harvesting
Animals were kept under a 12-hour light cycle and provided
food and water ad libitum. Animals were killed by asphyxiation
with CO2 (adults and weanlings) or by decapitation (neonates
and fetuses). Mice of both sexes were used together because no
differences in the results obtained were appreciated between
males and females. For RNA isolation and D3 enzymatic activ-
ity, tissues were dissected, immediately frozen on dry ice, and
stored at70°C until further use. Brain regions were identified
and harvested according to the mouse atlas by Paxinos and
Franklin (30). Animal procedures were approved by the Institu-
tional Animal Care and Use Committees of Dartmouth College
and the Maine Medical Center Research Institute. Genotyping
of the D3KO animals carrying the triple-point mutation was
performed by a PCR of genomic DNA from tail snips as previ-
ously described (8). Genotyping of mice carrying the novel de-
letion of theDio3 gene was performed by Southern analysis (see
below) or by a double PCR using a pair of primers that amplify
a DNA fragment of the native Dio3 gene and another pair of
primers that amplify a DNA fragment specific to the deleted
allele (Supplemental Methods).
Mouse embryonic stem (ES) cells and introduction
of mice carrying a deletion of Dio3
We (17) described the strategy used to target the Dio3 gene
using standard homologous recombination techniques.We used
the R1 ES cell line (31), which originated from the 129/Svmouse
strain. Targeted clones were identified by Southern analysis,
injected into C57/BL6 blastocysts and reimplanted in CD1 fos-
ter mothers. Chimeric males that showed germline transmission
were mated to C57/BL6 females to test for the germline trans-
mission of the mutation. Chimeric males were then mated with
129/Sv females to establish the mutant line in a 129/Sv
background.
D3 activity and serum levels of TH
D3 enzymatic activities were determined as previously de-
scribed (8). In brief, tissues were homogenized in a 10-mM
Tris-HCl, 0.25 sucrose buffer (pH 7.4). A suitable volume of
tissue homogenate was used in the enzymatic reaction to ensure
that deiodination do not exceed 40% and was proportional to
the amount of protein content. Tissue homogenates were incu-
bated at 37°C for an hour with 2 nM 125I-labeled T3 (PerkinEl-
mer) in the presence of 25 mM dithiothreitol. Deiodination was
determined based on the percentage of 125I-3,3-diiodothyro-
nine produced. The latter was determined by measuring the
amount of radioactivity associated with the reaction products
after separation by paper chromatography as described (32).
Total serum thyroid levels were determined using RIA kits fol-
lowing the manufacturer’s directions (TKT4 and TKT3; Sie-
mens). Serum TSH was determined by a RIA as previously de-
scribed (9).
DNA and RNA isolation and Northern and
Southern analysis
Total RNA and poly(A) RNA were isolated from brain
tissues using the RNAeasy kit (QIAGEN), including deoxyribo-
nuclease treatment, and the poly(A) kit from Ambion (Now
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Life Technologies).Dio3Northern analysis was performed fol-
lowing standard protocols. In brief, total and poly(A) RNA
samples were electrophoresed in a denaturing 1% agarose gel
containing formaldehyde and blotted onto a Nytran membrane
(GE Life Sciences). The blots were hybridized at 42°C in buffer
containing 50% formamide, washed with 0.1 saline sodium
citrate/0.1% sodium dodecyl sulfate at 65°C and autoradio-
graphed for 1–7 days. Probes were labeled with radioactive
32P-dCTP (MP Biomedicals, Inc) using the oligolabeling kit
(Pfizer) and were purified through G-50 columns (Pfizer). A
1.35-kb XhoI restriction fragment comprising the Dio3 coding
region and part of the 3-untranslated region was used as a
probe.
DNAwas isolated from tail snips using a kit from QIAGEN.
A Southern analysis was performed using standard protocols on
genomic DNA (gDNA) digested with EcoRI. A 0.7-kb SacI/
EcoRI restriction fragment located immediately outside the 5
end of the targeting sequencing was used as a probe.
RT-PCR analysis of allelic expression
Total RNA (1 g) was reverse transcribed for 1 hour at 42°C
with 1 L of Moloney murine leukemia virus reverse transcrip-
tase (Life Technologies). A reaction without the reverse tran-
scriptase was performed as a negative control to ensure no sig-
nificant amplification of gDNA in the downstream PCR. The
mix was heated at 75°C for 15 minutes to inactivate the reverse
transcriptase and diluted 1 to 20 with water. Aliquots of the
mixes from a given experiment were pooled before dilution to
establish the first point of an internal standard. Three consecu-
tive one to four dilutions of this standard were done to generate
three additional standard points. Ten microliters of each of the
diluted samples were mixed with 12.5L of SYBR Select master
mix from Life Technologies and 2.5 L of the appropriate gene-
specific primer mix (3.33 pmol/L each). The mixture was sub-
jected to PCR cycling using a MyiQ single color real-time PCR
detection system from Bio-Rad Laboratories. The PCRs were
performed in triplicate, and data for each gene and sample were
read from the standard curve.Gapdhwas used as a control gene,
its expression level not varying significantly between experimen-
tal groups. The expression levels for each gene are reported in
arbitrary units, after correction by Gapdh expression. The se-
quences of the primers used are shown in Supplemental
Methods.
Bisulfite sequencing of the intergenic differentially
methylated region (IG-DMR)
The sodium bisulfite sequencing methylation assay was per-
formed as described (33) using 500 ng to 1 g of DNA from
129/Sv mouse tissues of the neonatal age (P1). Briefly, two in-
dependent PCR replicates were performed using bisulfite-
treated DNA as template. PCR products were gel purified, com-
bined, and cloned using the TopoTA cloning kit (Invitrogen).
Clones were analyzed and sequenced at the McGill University
and Genome Québec Innovation Centre sequencing platform.
Duplicate clones or clones with incomplete C-to-U conversion
were excluded from the analysis. Information about the se-
quence and CpG groups analyzed can be found in Supplemental
Methods.
Pyrosequencing
Bisulfite conversion and pyrosequencing was carried out
according to Sun et al (34) with the following modifications:
gDNA (1 g) was treated using the Imprint DNA modifica-
tion kit (Sigma) in accordance with the manufacturer’s in-
structions for the two-step conversion and eluted in 20 L.
Primer sequences, annealing temperatures, and cycle number
are shown in Supplemental Methods. Pyrosequencing was
performed on the PSQ HS96 system using PyroGold Q96
SQA reagents (QIAGEN). The degree of methylation at CpG
sites (without distinguishing between maternal and paternal
alleles) was determined by pyro-Q CpG software (Biotage).
Information about the sequence and CpG groups analyzed
can be found in Supplemental Methods.
Statistics
We used the GraphPad Prism software for statistical analy-
sis. Unless stated otherwise, differences between more than two
experimental groups were determined by ANOVA and Tukey’s
post hoc test, whereas differences between two groups were
determined by the Student’s t test. P  .05 was considered sta-
tistically significant.
Results
Paternal inheritance of the mutated Dio3 allele
leads to a milder gross phenotype than that in
null Dio3 mice
Given that Dio3 is preferentially expressed from the pa-
ternally inherited allele (16, 17), one would predict that
heterozygous animals that inherited the mutation from
the father (Dio3 m/p) would manifest a phenotype
similar to that of a homozygousDio3/mutant. Such is
at least partially the case; mice with the Dio3 m/p
genotype had a significantly milder phenotype than mice
that were completely D3 deficient (8). For example, un-
like Dio3/ mice, adult Dio3 m/p mice do not ex-
hibit significant changes in their serum levels of thyroid
hormones, when compared with the wild types (Dio3/)
or with heterozygous animals with maternal inheritance
of the mutation (Dio3 m/p mice) (data not shown)
(10). However, an increased serum level of T3 and a par-
tially suppressed serumT4 level are noted at postnatal day
(P) 2 (Figure 1, A and B). At this age, serum TSH trended
lower (68.44  10.09 mU/L in Dio3 m/p mice vs
85.85 11.65 mU/L inDio3m/pmice, n 4 and 5),
but the difference was not statistically significant. These
thyroid parameters indicate neonatal overexposure to T3
and partial thyroid axis suppression in Dio3 p/m
mice. They are also significantly growth retarded and the
weight of their testes is reduced (Figure 1, C andD). These
abnormalities indicate that reducedDio3 dosage has phe-
notypic consequences. However, these gross phenotypes
are significantly milder than those in Dio3/ mice.
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Previous observations indicated that P2 Dio3/ mice
feature a 5-fold increase in serumT3, an 80% reduction in
serum T4, and a 30% reduction in weight as young adults
(8). Testes size in young Dio3 / males is also reduced
60%, when compared with Dio3/ littermates (unpub-
lished observations, Hernandez, A.). Compared with that
of Dio3/ mice, the milder phenotype of Dio3 m/p
mice suggests that Dio3 expression from the maternal
allele is partially compensating the lack of expression
from the paternal allele in these animals.
Dio3 is preferentially expressed from one allele in
mouse ES cells
We have previously reported the targeting of theDio3
gene in mouse ES cells to generate a mouse deficient in the
type 3 deiodinase (17). We have used Dio3 targeted and
nontargeted ES cell clones from that experiment to ana-
lyze Dio3 expression. Targeted clones are heterozygous
for a Dio3 mutation that introduces an XbaI restriction
site in the selenocysteine codon, thus rendering the en-
zyme inactive (35). We prepared gDNA and cDNA from
Dio3-targeted clones and used PCR to amplify a DNA
fragment containing the inserted Dio3 mutation. XbaI
digestion of these fragments (Figure 2A) revealed partial
digestion when the fragment had a gDNA origin, whereas
almost complete digestion occurs when the fragment was
amplified from cDNA generated by reverse transcription
of total RNA. Sequencing of the mutation site in these
fragments demonstrated that mutated DNA accounts for
approximately half of the gDNA but for a much higher
percentage of the RNA-derived cDNA (Figure 2B). Simi-
lar results were obtained for all fiveDio3-targeted clones.
In addition, D3 activity in these targeted clones was less
than 20% of the average D3 activity measured in nontar-
geted clones (Figure 2C). These results indicate not only
that Dio3 is preferentially expressed from one of the al-
leles in mouse ES cells but also that the preferentially
expressed allele is targeted more frequently in the homol-
ogous recombination event.
Dio3 allelic expression in the fetal head
Previous data suggested that allelic contribution to
Dio3 expression may be only slightly biased toward the
paternal allele in the fetal head (17).We have analyzed the
allelic contribution to Dio3 expression in the fetal eye,
brain, and the rest of craniofacial structures. We used
animals generated by reciprocal matings of Dio3/ and
Dio3/mice so that we could track the parental origin of
the mutated allele in the offspring and thus the allele that
is contributing to Dio3 expression (8). Fetal eye D3 ac-
tivities in heterozygous mice that inherited the mutation
from the father (Dio3 m/p) were similar to that in
heterozygous mice that inherited the mutation from the
mother (Dio3 m/p), and both were approximately
50%ofD3 activitymeasured inwild-type (Dio3/) mice
(Figure 3A). D3 activity in the brain ofDio3m/pmice
was 20% lower than in Dio3/ mice, whereas it was
significantly higher than in Dio3 m/p mice, in which
D3 activity was reduced 55%comparedwith that inwild-
type mice. In the tissues comprising the rest of the head
and craniofacial structures, D3 activity in Dio3 m/p
mice was not significantly reduced compared with that of
wild-type animals, but a 75% reduction was observed in
Dio3 m/p mice (Figure 3A), indicating strong prefer-
ential expression from the paternal allele in this tissue.
Dio3 mRNA expression from the mutated allele was
evaluated by real time quantitative PCR using primers
specific for the mutated Dio3 allele. Mutated Dio3
mRNAwas expressed at similar levels in the eyes ofDio3
m/p and Dio3 m/p fetuses (Figure 3B). In the
Figure 1. Altered phenotypes in heterozygous mice with paternal inheritance of the mutated Dio3 allele. A and B, Serum levels of T3 and T4 at
P2. Data represent the mean  SEM of determinations performed on five to eight serum samples. For each experimental group, each sample is
composed of pooled serum from two to three individual mice of both sexes. *, P  .01 as determined by ANOVA and Tukey’s post hoc test. C,
Weight. Data represent the mean  SEM of weights measured in 8–12 animals per experimental group. Only animals born to litters of five to
seven pups in size were included. *, P  .01 as determined by ANOVA and Tukey post hoc test. D, Testicular weight relative to body weight. Data
represent the mean  SEM of weights measured in eight, 18, 28, and 22 animals, respectively. *, P  .01 as determined by Student’s t test.
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brain, the expression of the mutated Dio3 mRNA was
reduced in Dio3 m/p fetuses compared with that in
Dio3 m/p fetuses. In the rest of the fetal head, this
reduction was more marked, indicating a stronger pref-
erential Dio3 expression from the paternal allele. These
activity measurements indicate a strong correlation be-
tween Dio3 mRNA and protein levels and confirm the
previously defined imprinting pattern based on mRNA
expression levels.
Figure 2. Preferential allelic expression of Dio3 in mouse ES cells. A,
Representative Southern analysis of restriction fragments from gDNA
and cDNA of an ES cell clone in which one allele of Dio3 has a triple-
point mutation creating an XbaI restriction site. A DNA fragment
containing the mutation was amplified by PCR, digested with XbaI,
and submitted to Southern analysis using a Dio3 cDNA as a probe. A
plasmid that was linearized as a result of XbaI activity was included as
an internal control of XbaI digestion. Initial PCR band and products of
XbaI digestions are marked by arrows. The band not pointed at by
arrows is a DNA heteroduplex PCR artifact not susceptible to XbaI
digestion. RT, reverse transcriptase. B, Genomic DNA and RNA-derived
cDNA sequence of the triple-point mutation in a targeted ES cell clone.
C, D3 activity in 5 Dio3-targeted clones and 10 nontargeted clones.
Data represent the mean  SEM. *, P  .01 as determined by
Student’s t test.
Figure 3. Dio3 allelic expression varies in the E15.5 fetal head. A, D3
activity in the eye, brain, and the rest of head structures of E15.5
mouse fetuses. Bars represent the mean  SEM of 36, 14, 22, 38, 14,
27, 14, seven, and 11 individual samples. Data are expressed as a
percentage of wild-type values. *, #, P  .01 vs Dio3/ and Dio3
m/p, respectively, as determined by ANOVA and Tukey’s post hoc
test. B, mRNA expression of the mutated allele. Bars represent the
mean  SEM of six determinations, and data are expressed as a
percentage of the values for Dio3 m/p mice. *, P  .01 as
determined by the Student’s t test. C, Northern analysis of fetal head
RNA. Total RNA (20 g) was used for eye and head, whereas polyA
enriched RNA (5 g) was used for brain. RNA samples were pooled
from at least three different animals. Cyclophilin hybridization (Cy) is
shown for informative purposes only because the purpose of this
experiment was to assess the relative abundance of mutated and wild-
type Dio3 within a specific pooled sample.
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Because the rodent brain expresses Dio3 transcripts
that are larger than the 2.2-kb transcript (7) that is most
abundant in placenta and fetal tissues, we also performed
a Northern analysis of mRNA from fetal tissues. These
samples were extracted from mice in which the neomycin
cassette used for targeting in ES cells was still present in
the 3-untranslated region of the Dio3 mRNA (17). As a
result, the Dio3 mRNA species carrying the mutation is
approximately 2 kb larger than the native Dio3 mRNA.
As expected, Dio3 mRNA transcripts above 4 kb in size
are detected in tissues from Dio3/ animals. In the fetal
eye and nonneural craniofacial structures of the wild-type
mice, the typical 2.2-kb transcript is essentially the only
one detected (Figure 3C), whereas a larger, similarly
abundant, 2.7-kb Dio3 transcript is also observed in the
wild-type fetal brain (Figure 2C, lanes 1, 4, and 7). The
abundance of the mutated 4-kb and the native 2.2-kb
Dio3 transcript is similar in the eye of Dio3 m/p and
Dio3m/p animals (Figure 3C, lanes 2 and 3), indicat-
ing biallelic Dio3 expression in this tissue. However, in
the nonneural head samples, the mutated transcript
was much more abundant than the native transcript in
Dio3 m/p mice, whereas the native Dio3 transcript
was much more abundant than the mutated one in Dio3
m/p mice (Figure 3C, lanes 8 and 9), demonstrating
strong preferential expression from the paternal allele.
Similarly, in the fetal brain Figure 3C, (lanes 5 and 6),
transcripts that originated in the paternal allele are also
more abundant, although the pattern is not as marked as
in the tissues contained in the rest of the head. Overall,
these results indicate no imprinting ofDio3 in the fetal eye
and marked preferentialDio3 expression from the pater-
nal allele in the craniofacial tissue and, to a lesser degree,
in the fetal brain.
Dio3 allelic expression in the
perinatal brain
Based on D3 activity data, brain
Dio3 follows a similar pattern of al-
lelic expression in late gestation. At
embryonic day (E) 18.5, Dio3 ex-
pression is reduced in the forebrain
and hindbrain of Dio3 m/p ani-
mals comparedwith that ofDio3/
mice (Figure 4A), but it is reduced
significantly further in Dio3 m/
p, indicating preferential expres-
sion from the paternal allele. At P1,
a marked imprinting pattern of ex-
pression is observed in the thalamus
and hypothalamus, with normal and
very reduced Dio3 expression in Dio3 m/p and Dio3
m/p animals, respectively (Figure 4B). No imprinted
pattern of expression is noticed in the cerebellum, in
which Dio3 expression seems equally biallelic. A relaxed
pattern of imprinting is observed in the cerebral cortex
and the midbrain and pons. In this case, significant pref-
erential expression from the paternal allele is noted, but it
is not sufficient to achieveDio3 expression levels compa-
rable with those in wild-type mice (Figure 4B). Lack of
Dio3 imprinting is noted in certain nonneural tissues,
such as the newborn testes (Figure 4B).
Dio3 allelic expression in the late postnatal brain
Northern analysis of P7 brain mRNA reveals that the
larger 2.7-kb Dio3 transcript is the only one detected in
the neocortex (Figure 5A, left panel) and does not show
significant preferential allelic expression; mutated (and
larger because it contains the neomycin cassette) and the
wild-type version of this RNA species appear similarly
abundant inDio3m/p andDio3m/pmice. Quan-
tification of the mutatedDio3mRNA species reveals sim-
ilar levels of expression in heterozygous mice, irrespective
of the parental origin of the mutated allele (Figure 5B, left
panel). In a P7 specimen comprising the thalamus, hip-
pocampus, and striatum, both 2.2- and 2.7-kbDio3 tran-
scripts are detected, the latter being more abundant (Fig-
ure 5A, right panel). In this tissue, the pattern of allelic
expression in Dio3 m/p and Dio3 m/p mice still
shows significant preferential expression from the pater-
nally inherited allele (Figure 5, A and B, right panel).
At P21,Dio3/mice exhibit wide variation inDio3
expression levels across brain regions, D3 activity being
very high in the hypothalamus and in the cortex, striatum,
and hippocampus; low in the cerebellum, midbrain, and
pons and in the corpus colliculus; and intermediate in the
amount in the olfactory bulb and thalamus (Figure 5C).
Figure 4. Dio3 allelic contributions to D3 activity vary in the perinatal brain. A and B, D3 activity
in regions of the perinatal brain in Dio3/, Dio3 m/p, and Dio3 m/p mice. Data
represent the mean  SEM of 18, four, and seven determinations (A) or eight determinations (B).
*, #, P  .01 vs Dio3/ or Dio3 m/p, respectively, as determined by ANOVA and Tukey’s
post hoc test. WT, wild type.
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At this age, thalamic and cerebellar Dio3 shows no im-
printing pattern of expression, D3 activity being compa-
rable in Dio3 m/p and Dio3 p/m mice and signif-
icantly lower than in Dio3/ mice (Figure 5D). The rest
of the brain regions analyzed still exhibit preferential ex-
pression from the paternal allele, although the relative
contribution of this allele to overall Dio3 expression ap-
pears reduced compared with previous developmental
stages. Thus, at this stage, expression from the paternal
allele is sufficient to achieve normal levels of Dio3 ex-
pression in the midbrain and pons, corpus colliculus,
and the cortex, striatum, and hippocampus, whereas
the maternal allele can achieve more than 50% of the
normal levels of expression when the paternal allele is
mutated (Figure 5D).
Methylation of the IG-DMR and
maternally expressed gene 3 (Meg3) intron in
different tissues
To begin to address the mechanisms of the differences
in Dio3 imprinting between tissues, we analyzed the
methylation pattern of the IG-DMR (Figure 6A). This
region regulates imprinting in the Dlk1-Dio3 imprinted
domain and is usually methylated in the paternal allele in
the mouse fetus (36), in which it appears to play a role in
the repression of the maternal copy of Dio3 (28, 36).
First, the methylation status of 33 CpGs corresponding to
the IG-DMR (37) was assessed by bisulfite sequencing of
DNA isolated from the cerebellum and hypothalamus/
thalamus of P1 mice. We could not distinguish between
maternal and paternal alleles in these samples, but we
observed two types of clones from both tissues, either
hypomethylated or hypermethylated (Figure 6B). Overall
levels of methylation were comparable in both tissues
despite the observation that allelic expression of Dio3 is
different in those tissues, biallelic in the cerebellum and
preferentially paternal in the hypothalamus. This suggests
that loss of Dio3 imprinting in the cerebellum is not due
to changes in the methylation status of the IG-DMR.
Pyosequencing analysis of the methylation status of
seven CpG (CG5 to CG12) of the IG-DMR indicated
Figure 5. Dio3 allelic contribution to D3 activity vary in P7 and P21 brain regions. A, Northern blot analysis showing Dio3 mRNA transcripts in the
neocortex and thalamus/hippocampus/striatum (T/H/S) of Dio3/, Dio3 m/p, and Dio3 m/p P7 mice. PolyA-enriched RNA (5 g) from
four mice per group was used. B, Real-time PCR quantification of the Dio3 mRNA transcribed from the mutated allele in Dio3 m/p and Dio3
m/p P7 mice. Data represent the mean  SEM of five determinations. *, P  .01 as determined by the Student’s t test. C, D3 activity in brain
regions of P21 Dio3/ mice. Data represent the mean  SEM of eight determinations. D, D3 activity in brain regions of Dio3 m/p and Dio3
m/p P21 mice as compared with wild-type values (dotted line). Cb, cerebellum; CoC, corpus colliculus; CxStHi, cortex, striatum, and
hippocampus; H, hypothalamus; MP, midbrain and pons; OB, olfactory bulb; Th, thalamus; WT, wild type. Data represent the mean  SEM of
eight determinations. *, #, P  .01 vs Dio3/ or Dio3 m/p, respectively, as determined by ANOVA and Tukey’s post hoc test.
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approximately 50% methylation in the P2 cerebellum,
hypothalamus, and testis and in the fetal eye and face
(Figure 7, left panel).Modest but significant differences in
the degree of methylation were noticed at P2 between
craniofacial structures and the testis.
Using the same technique and the same tissues, we
analyzed the methylation status of a region at the 5-end
of the Meg3 gene (or gene trap locus 2, Gtl2), including
the first intron. This region is differentially methylated
between alleles and contains a putative binding site for the
zinc finger protein CCCTC binding factor (CTCF), which
plays a role in the regulation of imprinting (28) (Figure
6A). Overall methylation was in the range of 30% for all
tissues (Figure 7, right panel). Again, modest but signifi-
cant differences in methylation level were observed, with
fetal craniofacial structures exhibiting significantly lower
methylation than the neonatal testes and cerebellum.
In summary, the changes in methylation profiles are
associated with differences in Dio3 allelic expression in
some tissues, suggesting an impact on the regulation of
Dio3 genomic imprinting. But this is not the case for all
tissues, an observation that points to other tissue-specific
mechanisms influencing the epigenetic regulation of
Dio3.
Deletion of the Dio3 gene and promoter does not
change imprinting at the Dio3 locus
We have generated by homologous recombination in
mouse ES cells an additional mouse model in which an
approximately 4.5-kb genomic fragment between endog-
enous NotI and HindIII restriction sites has been deleted
in the Dio3 locus and replaced by the neomycin cassette
used for clone selection. The deleted fragment contains
the Dio3 exon, 1.8 kb of 3-flanking region and approx-
imately 500 bp of -flanking region including the Dio3
promoter (Figure 8A). A Southern blot analysis of EcoRI-
digested gDNA isolated from tail snips of wild-type mice
and mice heterozygous and homozygous for the deletion
demonstrated the germline transmission of the deletion
(Figure 8B). A Northern blot analysis of RNA isolated
from a pregnant uterus and fetal heads demonstrated the
absence of Dio3 mRNA in mice homozygous for the de-
letion (Dio3 Del /) (Figure 8C). Using this animal
model, we analyzed mRNA expression of neomycin and
Dio3 in various tissues of heterozygous animals with dif-
ferent parental inheritance of the deletion. In the fetal
liver, brain, and body of the fetus, neomycinmRNA levels
were much higher in animals with paternal inheritance of
the deletion (Dio3 Del m/p) than in heterozygous an-
imals that inherited the deletion from the mother (Dio3
Del m/p) (Figure 8D). Because neomycin mRNA is
expressed only from the deleted Dio3 allele, these results
indicate preferential expression from the paternal allele in
these tissues.
In contrast, the contribution to neomycin mRNA lev-
els was not significantly different between alleles in the
neonatal testes and the adult brain (Figure 8D). Essen-
tially the opposite pattern is observed for Dio3 mRNA
levels. Fetal tissueDio3mRNA levels were much lower in
animals with paternal inheritance of the deletion (Dio3
Del m/p) than in heterozygous animals that inherited
the deletion from the mother (Dio3 Del m/p) (Figure
8E). Again, contributions to theDio3mRNA levels in the
adult brain were similar between alleles (Figure 8E).
These tissue-specific imprinting patterns of neomycin and
Dio3mRNAs in this animalmodel recapitulate the results
obtained in theDio3mutationmousemodel, in which the
Dio3 gene and promoter are intact. These results demon-
strate that, at least in the tissues studied, the Dio3 pro-
Figure 6. Methylation status of the IG-DMR in the cerebellum and
hypothalamus/thalamus of P1 mice. A, Simplified diagram of genomic
elements studied in the Dlk1-Dio3 imprinted domain. B, Bisulfite
sequencing methylation assay of 33 CG pairs in DNA isolated from
tissues of Dio3/ mice. Closed circles indicate methylated CGs and
open circles indicate unmethylated CGs. Each row corresponds to a
particular methylation pattern, and the number of clones with each
pattern is indicated at the right. Overall methylation in all the clones
analyzed is indicated in parentheses for each tissue. Cb, cerebellum;
CoC, corpus colliculus; CxStHi, cortex, striatum, and hippocampus;
H, hypothalamus; MP, midbrain and pons; OB, olfactory bulb; Th,
thalamus.
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moter is not necessary for conferring tissue specificity to
the allelic expression at theDio3 locus. This is consistent
with studies indicating that imprinting control is medi-
ated by differentially methylated regions such as the
IG-DMR at the Dlk1-Meg3 part of the cluster. It also
shows that the normal imprinting pattern can be imposed
on the regulation of the phosphoglycerate kinase pro-
moter driving the neomycin gene; therefore, specific char-
acteristics of the Dio3 promoter do not confer sensitivity
to imprinting.
Discussion
In mice, the absence of a functional D3 enzyme leads to
systemic overexposure to T3 during development (8) and
to excessive TH action in certain adult tissues, such as the
CNS (14). Given the pleiotropic actions of TH, this over-
exposure leads to a number of abnormalities. Because
Dio3 is expressed from the paternal allele during fetal life
(16, 17), it is reasonable to expect that heterozygous an-
imals inheriting the Dio3 mutation from their fathers
(Dio3 m/p) would feature similar abnormalities. We
show herein that this is at least partly the case because
Dio3 m/p mice exhibit elevated serum T3 and sup-
pressed serum T4 as neonates,
growth retardation, and small tes-
tes. These findings are also observed
in theDio3 null mouse, but their se-
verity is significantly reduced in the
Dio3m/pmutant. Furthermore,
viability and fertility of Dio3 m/p
mice is significantly improved when
comparedwithDio3/mice,andtheir
serumTHlevels appearnormal inadult
life (10).Themoremoderatephenotype
observed in Dio3 m/p mice com-
paredwithDio3/mice is likelydueto
considerableDio3 expression from the
maternal allele in certain tissues.
We demonstrate that mouse ES
cell clones targeted for Dio3 inacti-
vation exhibit a high degree of
monoallelic Dio3 expression at the
mRNA and protein levels, suggest-
ing that strong genomic imprinting
of Dio3 is present around the blas-
tocyst stage of early development.
This is not surprising because most
imprinted genes, including those in
the Dlk1-Dio3 imprinted domain,
manifest such patterned expression
in ES cell lines and at early develop-
mental stages (38). It is remarkable that all five Dio3
targeted clones exhibited markedly deficient levels of
Dio3 expression, suggesting a significant bias in the ho-
mologous recombination event, which favored the pref-
erentially expressed, presumably paternal allele. This sug-
gests that the expression and associated alterations in
chromatin facilitate homologous recombination. The re-
sult is also consistent with observations that suggest the
existence of epigenetic boundaries that are associated
with a differential timing for DNA replication at im-
printed loci (39). If this is also the case for theDio3 locus,
it is then possible that gene targeting is facilitated when
the preferentially expressed allele is replicated.
Although marked preferential Dio3 expression from
the paternal allele is found in ES cells and the fetus as a
whole, it does not necessarily apply to all tissues and cell
types. Many imprinted genes exhibit tissue-specific pat-
terns of allelic expression (40, 41). We show that in the
fetal eye, both alleles contribute equally to Dio3 expres-
sion. The absence of Dio3 imprinting in this tissue sug-
gests that deficient expression from the paternal Dio3
allele only is less likely to have an impact on the retinal
and vision phenotype that is observed in Dio3 null mice
(42). The absence of Dio3 imprinting is also observed in
Figure 7. Methylation status of the IG-DMR and Meg3 intron in various tissues. Methylation
percentage of seven and five CpG pairs in the IG-DMR and the Meg3 intron, respectively, as
determined by pyrosequencing on DNA samples isolated from Dio3/ mice. Data represent the
mean  SEM of four determinations. *, P  .01 as determined by ANOVA and Tukey’s post hoc
test.
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the newborn testes. In this regard, the decrease in testis
size in Dio3 p/m mice is much less severe than in
Dio3/ mice (unpublished results, Hernandez, A.) and
may be due to the still significant neonatal exposure to
elevated circulating levels of T3 in these animals.
Other fetal tissues (eg, nonneural craniofacial tissue)
show a high degree of preferential expression from the
paternal allele, but it is the CNS that displays a wide
regional variation in the relative contributions from each
allele to overall Dio3 expression. Except for the cerebel-
lum, which exhibits equal Dio3 expression from both
alleles, most regions of the perinatal and late neonatal
brain exhibit preferential Dio3 expression from the pa-
ternal allele. However,Dio3 genomic imprinting appears
relaxed in some brain regions because the expression
from the paternal allele alone is not sufficient to achieve
normal Dio3 expression levels, and the expression from
the maternal allele is close to 50% of wild-type values in
some cases. Only the perinatal hypothalamus exhibits an
allelic expression pattern that is consistent with robust
genomic imprinting ofDio3, but even in this brain region,
the monoallelic pattern of expression is relaxed by wean-
ing age. The overall relaxation of genomic imprinting of
Dio3 by weaning age in most brain regions is consistent
with the reported late neonatal loss of imprinting ofDlk1
in neurogenic structures of the brain (43) and the in-
creased plasticity of brain imprinting for several genes in
the cluster (37). Thus, it is possible that common mecha-
nisms of imprinting loss or relaxation exist for the Dlk1-
Dio3 imprinted domain in the CNS and other tissues.
Different epigenetic mechanisms regulating the expres-
sion of the larger, approximately 2.7-kb Dio3 mRNA
transcript, expressed in themouse brain, may also explain
the relaxation ofDio3 imprinting in this tissue. In the fetal
brain, this transcript is as abundant as the better charac-
terized 2.2-kb transcript but becomes by far the most
abundant by P7, being the only Dio3 transcript detected
in the P7 neocortex byNorthern analysis. In the untreated
adult rodent brain, this transcript is also the most abun-
dant (7). Indirect evidence from the studies of DIO3 in
human cell lines (44) and preliminary observations in our
laboratory suggests that the larger Dio3 mRNA contains
additional sequence in the 5-untranslated region of the
mRNA, with transcription thus being directed by an un-
identified upstream promoter. It is thus possible, as ob-
served with other imprinted genes (41), that this alterna-
tive promotermay not be regulated by the same epigenetic
mechanisms. At a more specific cell and tissue level, it is
possible that other imprinting patterns of Dio3 expres-
sion exist. In this regard, Sittig et al (45) reported modest
preferential Dio3 expression from the maternal allele in
the hippocampus of a rat model of developmental alcohol
Figure 8. Allelic expression in the Dio3 locus in the absence of Dio3 gene and promoter. A, A mouse model was generated featuring an
approximately 4.5-kb deletion and replacement with phosphoglycerate kinase-neo that included the Dio3 gene and promoter (Dio3Del/). B,
Southern blot analysis after EcoRI digestion of tail snip DNA isolated from Dio3/, Dio3Del/, and Dio3Del/ mice. C, Northern blot analysis of
Dio3 2.2-kb mRNA transcript in the pregnant uterus and fetal head of Dio3/ and Dio3Del/ mice, demonstrating the absence of Dio3 mRNA in
mice homozygous for the deletion. Total RNA (20 g) was used. Cyclophilin mRNA is shown as an estimation of the relative RNA loaded. D and E,
Real-time PCR quantification of neomycin (D) and Dio3 (E) mRNA in several tissues of Dio3Del m/p and Dio3Del m/p mice. Tissues include E16.5
fetuses (excluding the head and the liver), E16.5 liver and brain, P90 brain, and P5 testes. Data are represented as a percentage of expression from
the paternal allele. Data represent the mean  SEM of determinations in six (neomycin mRNA) or three to five (Dio3 mRNA) animals per group.
*, P  .01 as determined by the Student’s t test.
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exposure, whereas Correa et al (46) reported preferential
Dio3 expression from the maternal allele in pancreatic
-cells.
The varied tissue and developmental patterns of Dio3
allelic expression suggest the existence of tissue-specific
mechanisms of epigenetic regulation of Dio3 expression.
An analysis of themethylation status of two regions in the
imprinted domain with known regulatory roles on allelic
Dio3 expression (36), the IG-DMR and theMeg3 intron,
reveal subtle differences in the degree of methylation be-
tween some tissues. Although statistically significant,
these differences are rather small and may not explain the
allelic expression observed in a given tissue. For instance,
Dio3 is not imprinted in the neonatal testes and cerebel-
lum. These tissues show increased Meg3 intron methyl-
ation compared with fetal craniofacial tissue, in which
Dio3 is imprinted. In this case, the difference in methyl-
ation is associated with a difference in the ratio of allelic
expression. However, Meg3 intron methylation in the
newborn hypothalamus, in which Dio3 imprinting is ro-
bust, is similar to that in testes and cerebellum, which
show no Dio3 imprinting. It is thus uncertain whether
these methylation differences influence the observed tis-
sue specific pattern of allelic Dio3 expression.
Studies on a new mouse model in which theDio3 gene
and its characterized promoter are deleted and substi-
tuted by the neomycin gene driven by a different putative
promoter reveal no significant role for the endogenous
Dio3 promoter in mediating tissue-specificDio3 imprint-
ing. At least for the tissues analyzed in this mouse model,
the patterns of neomycin and Dio3 allelic expression re-
semble those observed for the intact and mutated allele in
mice carrying theDio3mutation. This demonstrates that
sequences in the endogenous Dio3 promoter are not rel-
evant in mediating the tissue specificity of Dio3 allelic
expression. Although transcription of the antisense
Dio3os gene may be affected in mice carrying this dele-
tion, our results indicate that this mouse model can be a
useful tool for imprinting studies and for other types of
investigations that benefit from the absence of the Dio3
mRNA and protein.
Overall, our observations indicate that genomic im-
printing of Dio3 varies significantly between tissues, de-
velopmental stages, and Dio3 transcripts. This applies in
particular to the brain, an organ in which Dio3 is prom-
inently expressed throughout life. It is possible that the
extent of control conferred by the IG-DMR may differ
between one tissue and another; becauseDio3 is the most
distant from the IG-DMR end of the cluster, it may be
more prone to distance effects, resulting in the loss of
Dio3 imprinting in some contexts. This likely explains the
less severe gross phenotype of heterozygous mice with
inactivation of the paternalDio3 allele (as comparedwith
null mice) and suggests that certain abnormalities of the
Dio3 null mice will be more likely to occur than others
when imprinting of Dio3, and thus Dio3 dosage, is dis-
rupted. In that context, it is likely that phenotypes that
originate in tissues with high Dio3 expression and a
marked pattern ofmonoallelic expressionwill be themost
susceptible to abnormal epigenetic regulation of Dio3.
Future studies will address this hypothesis.
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